Dr DeAngelo on the Importance of Consensus Guidelines for Treating Acute Lymphoblastic Leukemia

Daniel DeAngelo, MD, PhD, chief, Division of Leukemia, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, highlights the challenges of treating acute lymphoblastic leukemia (ALL), a rare malignancy that accounts for a small proportion of leukemia cases. Given the disease’s relative infrequency outside of large academic centers, standardizing diagnostic and therapeutic approaches is essential for ensuring consistent care. These considerations were discussed at the Bridging The Gaps: Leukemia, Lymphoma, and Multiple Myeloma meeting in Miami, Florida.